Wolters Kluwer Health
may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

Objective: Many US firms offer influenza vaccination clinics to prevent lost productivity due to influenza. Strategies to promote and offer vaccination differ, and the economic value of the strategies is unknown.

Results: On-site influenza vaccination was generally cost-saving over no vaccination. For the scenario of vaccine effectiveness of 70% and intermediate transmissibility, the incremental costs per employee for a firm of 50 employees were −$6.41 (ie, cost savings) for inactivated vaccine only versus no vaccination, −$1.48 for vaccine choice versus inactivated vaccine, and $1.84 for vaccine choice plus incentive versus vaccine choice. Clinics offering a choice of vaccines were slightly less costly under many scenarios. Generally, incremental costs were lower (1) in larger firms; (2) when influenza was assumed to be more contagious; and (3) when vaccine effectiveness was assumed to be higher.

From the Department of Family Medicine (Drs Zimmerman, Nowalk, and Lin), University of Pittsburgh, Pittsburgh, PA; Public Health Computational and Operations Research (PHICOR) (Ms Wiringa, Ms Mitgang, and Dr Lee), University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, PA; and MedImmune, LLC (Dr Rousculp), Gaithersburg, MD.

Conflicts of Interest: University of Pittsburgh Department of Family Medicine (RKZ, MPN, and CJL): MedImmune, LLC (RKZ, MPN, CJL); Sanofi (RKZ, CJL), Investigator Initiated Research grant; and Merck (RKZ, MPN, CJL) Investigator Initiated Research grant. University of Pittsburgh Public Health Computational and Operations Research (AEW, EAM, and BYL): MedImmune, LLC. Dr Rousculp was a MedImmune employee at the time of this study.